Literature DB >> 7955812

Metabolism of nicotine to cotinine studied by a dual stable isotope method.

N L Benowitz1, P Jacob.   

Abstract

OBJECTIVES: (1) To determine the disposition kinetics of nicotine and cotinine, including the fractional conversion of nicotine to cotinine, (2) to compare the disposition kinetics of deuterium-labeled and unlabeled cotinine, and (3) to develop a pharmacokinetically based method for estimating daily intake of nicotine from cigarette smoking. STUDY
DESIGN: Twenty cigarette smokers received a combined infusion of deuterium-labeled nicotine (d2) and cotinine (d4). Six nonsmokers received a combined infusion of unlabeled cotinine, cotinine-d2 and cotinine-d4. Daily intake of nicotine was estimated with use of the plasma cotinine concentration during ad libitum smoking, clearance of labeled cotinine, and fractional conversion of nicotine to cotinine.
RESULTS: The kinetics of labeled versus unlabeled cotinine and of cotinine in smokers versus nonsmokers were similar. On average, 72% of nicotine was converted to cotinine, with a range from 55% to 92%. Subjects with lower clearances of nicotine had lower fractional conversion of nicotine to cotinine, indicating that this is the most rapid of the proximate metabolic pathways for nicotine. The equation for estimating daily intake of nicotine from smoking was: Dnic (mg/24 hr) = K x (Plasma Cot) (ng/ml), where K averaged 0.08, with a range from 0.047 to 0.102. Individual variability in the clearance of cotinine (coefficient of variation, 27.5%) accounts for more of the variability in K than does variability in the fractional conversion of nicotine to cotinine (coefficient of variation, 12.3%).
CONCLUSIONS: Our study provides quantitative data on individual variability in the extent of C-oxidation of nicotine to cotinine and a quantitative perspective on the use of plasma cotinine as an indicator of daily intake of nicotine from tobacco.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7955812     DOI: 10.1038/clpt.1994.169

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  139 in total

1.  Population pharmacokinetic model of transdermal nicotine delivered from a matrix-type patch.

Authors:  Matthew W Linakis; Joseph E Rower; Jessica K Roberts; Eleanor I Miller; Diana G Wilkins; Catherine M T Sherwin
Journal:  Br J Clin Pharmacol       Date:  2017-09-06       Impact factor: 4.335

2.  Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars, and pipes.

Authors:  P Jacob; L Yu; A T Shulgin; N L Benowitz
Journal:  Am J Public Health       Date:  1999-05       Impact factor: 9.308

Review 3.  Positive and negative effects of alcohol and nicotine and their interactions: a mechanistic review.

Authors:  Laura L Hurley; Robert E Taylor; Yousef Tizabi
Journal:  Neurotox Res       Date:  2011-09-20       Impact factor: 3.911

Review 4.  Hair as a biomarker for exposure to tobacco smoke.

Authors:  W K Al-Delaimy
Journal:  Tob Control       Date:  2002-09       Impact factor: 7.552

5.  Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers.

Authors:  J O'Loughlin; G Paradis; W Kim; J DiFranza; G Meshefedjian; E McMillan-Davey; S Wong; J Hanley; R F Tyndale
Journal:  Tob Control       Date:  2004-12       Impact factor: 7.552

6.  Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics.

Authors:  Nael Al Koudsi; Jill C Mwenifumbo; Edward M Sellers; Neal L Benowitz; Gary E Swan; Rachel F Tyndale
Journal:  Eur J Clin Pharmacol       Date:  2006-04-28       Impact factor: 2.953

7.  Salivary cotinine concentration versus self-reported cigarette smoking: Three patterns of inconsistency in adolescence.

Authors:  Denise B Kandel; Christine Schaffran; Pamela C Griesler; Mei-Chen Hu; Mark Davies; Neal Benowitz
Journal:  Nicotine Tob Res       Date:  2006-08       Impact factor: 4.244

8.  Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors.

Authors:  Nael Al Koudsi; Ewa B Hoffmann; Abbas Assadzadeh; Rachel F Tyndale
Journal:  Eur J Clin Pharmacol       Date:  2009-12-09       Impact factor: 2.953

9.  Utility and relationships of biomarkers of smoking in African-American light smokers.

Authors:  Man Ki Ho; Babalola Faseru; Won S Choi; Nicole L Nollen; Matthew S Mayo; Janet L Thomas; Kolawole S Okuyemi; Jasjit S Ahluwalia; Neal L Benowitz; Rachel F Tyndale
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 10.  The benefits of stopping smoking and the role of nicotine replacement therapy in older patients.

Authors:  S G Gourlay; N L Benowitz
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.